Creative Planning
KDNY

Creative Planning’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Creative Planning’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,500
Closed -$94K – 2148
2017
Q4 		$94K Buy
2,500
+320
+15% +$14K ﹤0.01% 1736
2017
Q3 		$116K Sell
2,180
-430
-16% -$25.5K ﹤0.01% 1696
2017
Q2 		$149K Sell
2,610
-390
-13% -$19.6K ﹤0.01% 1701
2017
Q1 		$161K Buy
3,000
+1,275
+74% +$72K ﹤0.01% 1628
2016
Q4 		$98K Sell
1,725
-1,075
-38% -$65K ﹤0.01% 1886
2016
Q3 		$174K Hold
2,800
– – ﹤0.01% 1475
2016
Q2 		$158K Buy
+2,800
New +$170K ﹤0.01% 1390

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's KDNY Position: Q1 2018 in Review

Creative Planning sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2018, closing a stake of 2,500 shares — an estimated $94K sold.

Creative Planning first reported a position in KDNY in Q2 2016 and held it in 7 quarters. The position peaked at $174K in Q3 2016. 92 funds tracked by Wall St. Rank hold KDNY as of Q1 2018.

  • Creative Planning reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Creative Planning sold 2,500 Chinook Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $94K.
  • Creative Planning first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
  • Creative Planning's Chinook Therapeutics, Inc. Common Stock position peaked at $174K in Q3 2016.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Creative Planning's 13F filing for Q1 2018, filed 18 Apr 2018.